Brought to you by 
Cortendo Invest licenses DiObex rights to cortisol inhibitors
03 Apr 2018
Executive Summary
Swedish pharmaceutical company Cortendo Invest AB (specializes in cortisol regulators) has licensed biotech firm DiObex (developing drugs against metabolic diseases) exclusive worldwide development and marketing rights to its cortisol synthesis inhibitors for metabolic diseases, including all related patents, patent applications, IP, and other assets.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cortendo Invest licenses DiObex rights to cortisol inhibitors
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice